Photocure ASA (PHCUF)
| Market Cap | 120.59M -19.7% |
| Revenue (ttm) | 71.39M +27.4% |
| Net Income | 5.06M +2,192.1% |
| EPS | 0.19 +2,251.3% |
| Shares Out | n/a |
| PE Ratio | 29.26 |
| Forward PE | 178.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 5.65 |
| Previous Close | 6.01 |
| Day's Range | 5.65 - 5.65 |
| 52-Week Range | 5.58 - 7.39 |
| Beta | 0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Photocure ASA
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia. The company has a license agreement with Asieris MediTech Co to develop... [Read more]
Financial Performance
In 2025, Photocure ASA's revenue was 532.58 million, an increase of 1.37% compared to the previous year's 525.39 million. Losses were -1.52 million, -54.58% less than in 2024.
Financial numbers in NOK Financial StatementsNews
Photocure Provides Update on AssureMDx and Anticipated Medicare Coverage Timeline
OSLO, Norway, Nov. 9, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today provides an update on AssureMDx™ and progress since the acquisition of Vesica Health on June 4, 2...
Photocure ASA Earnings Call Transcript: Q3 2026
Q3 product revenue rose 7% at constant currency, with growth in both regions and stronger U.S. account adoption. FY 2026 product growth guidance increased to 10%–12%; longer-term targets include >25% revenue CAGR through 2030.
Photocure ASA Slides: Q3 2026
Photocure ASA has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 28, 2026.
Photocure ASA Quarterly report: Q3 2026
Photocure ASA has published its Q3 2026 quarterly earnings report on October 28, 2026.
Photocure ASA: Results for the third quarter of 2026
OSLO, Norway, Oct. 28, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix® /Cysview® revenues of NOK 134.2 million in the third quarter of 2026 (Q3 2025: NOK 134.1 million), and Adju...
Photocure ASA - New CFO Appointed
OSLO, Norway, October 22, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, is today announcing that Dennis Camporeale has been appointed as Chief Financial Officer, effective...
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II
OSLO, Norway, Aug. 14, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced that the U.S. Food and Drug Administration (FDA) has published a proposed order in th...
Photocure ASA Earnings Call Transcript: Q2 2026
Q2 2026 saw 11% product revenue growth ex-FX, driven by strong North American and European performance, equipment upgrades, and mobile BLC adoption. The Vesica Health acquisition and FDA reclassification are set to expand market access, with guidance raised to 8%-11% top-line growth and long-term targets of 25%+ annual revenue growth and EBITDA margins by 2030.
Photocure ASA Slides: Q2 2026
Photocure ASA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Photocure ASA Quarterly report: Q2 2026
Photocure ASA has published its Q2 2026 quarterly earnings report on July 29, 2026.
Photocure ASA: Results for the second quarter of 2026
OSLO, Norway, July 29, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 140.0 million in the second quarter of 2026 (Q2 2025: NOK 135.6 million), and an...
Photocure ASA Transcript: M&A announcement
The acquisition of Vesica Health and AssureMDx enables expansion into precision diagnostics, leveraging commercial synergies and robust clinical validation. Structured milestone payments and multiple reimbursement pathways reduce risk, with significant long-term growth expected from 2027 onward.
Photocure ASA Press release: M&A announcement
Photocure ASA issued a press release on June 5, 2026, disclosing material business information to investors.
Photocure ASA Slides: M&A announcement
Photocure ASA has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
OSLO, Norway, June 4, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), a leader in bladder cancer diagnostics, today announced the signing and successful completion of its acquisition of Vesica Health, ...
Photocure ASA Earnings Call Transcript: Q1 2026
Q1 2026 saw 18% product revenue growth, strong gains in both North America and Europe, and 12 consecutive quarters of positive EBITDA. Regulatory and commercial milestones, including FDA reclassification and new partnerships, position the business for scalable long-term growth.
Photocure ASA Quarterly report: Q1 2026
Photocure ASA has published its Q1 2026 quarterly earnings report on May 7, 2026.
Photocure ASA Slides: Q1 2026
Photocure ASA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Photocure ASA: Results for the first quarter of 2026
OSLO, Norway, May 7, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 139.0 million in the first quarter of 2026 (Q1 2025: NOK 125.3 million), and an ad...
Photocure ASA: Update on Regulatory Classification for OAY Equipment
OSLO, Norway, April 13, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today announced that the U.S. Food and Drug Administration (FDA) has communicated to Photocure that it plans to issue a proposed o...
Photocure ASA Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw strong revenue and EBITDA growth, driven by North America and EU expansion, new partnerships, and product upgrades. Operating leverage improved, with 11 straight quarters of positive EBITDA and a robust cash position. Guidance calls for 7%-11% growth and continued scaling.
Photocure ASA Quarterly report: Q4 2025
Photocure ASA has published its Q4 2025 quarterly earnings report on February 18, 2026.
Photocure ASA Slides: Q4 2025
Photocure ASA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 18, 2026.
Photocure ASA Annual report: Q4 2025
Photocure ASA has published its Q4 2025 annual report on February 18, 2026.
Photocure ASA: Results for the fourth quarter of 2025
OSLO, Norway, Feb. 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 135.1 million in the fourth quarter of 2025 (Q4 2024: NOK 128.6 million), and a...